What if the antidepressants meant to stabilize a mother’s mental health during pregnancy could also pose a risk to her unborn child?
At a Glance
- Debate on antidepressant safety in pregnancy has persisted for decades.
- FDA warns about potential risks but lacks conclusive evidence.
- Experts emphasize individualized risk-benefit analysis.
- Paroxetine remains particularly controversial due to heart defect risks.
The Historical Debate Over Antidepressants in Pregnancy
Antidepressants during pregnancy are the medical equivalent of the age-old debate about whether pineapple belongs on pizza: fiercely contested with passionate arguments on both sides. The saga began with SSRIs in the late 20th century, ushering in an era of hope for treating maternal depression. However, shadows loomed large, thanks to the thalidomide tragedy of the 1950s and 60s, which taught us to tread carefully with medications in pregnancy. Concerns about antidepressants causing birth defects have lingered ever since.
Approximately 5% of pregnant women take an SSRI for depression. But SSRI use during pregnancy has been linked in observational studies to birth defects, miscarriages, and neurological and behavioral challenges in childhood.
On Monday, July 21 at 10 a.m. ET, we’ll be hosting an… pic.twitter.com/pz32xAsGfr
— Dr. Marty Makary (@DrMakaryFDA) July 17, 2025
In the early 2000s, as studies on SSRIs and pregnancy risks began to multiply like rabbits, the medical community found itself in a pickle. The FDA, in 2005, slapped a warning on paroxetine, citing an increased risk of fetal heart defects. But like any good soap opera, the plot thickened with conflicting results from subsequent studies. The debate raged on: are antidepressants the hero in the story of maternal mental health, or the villain threatening fetal safety?
Watch: What Antidepressants Are Safe During Pregnancy?
The Players in the Antidepressant Arena
Enter the key players: regulatory agencies like the FDA, professional societies, and critics of psychiatry. Each has their script, motivations, and roles. While regulatory agencies focus on public safety and updating drug labels, professional societies advocate for evidence-based care. Critics, meanwhile, cry foul over overmedication and warn of potential teratogenic effects. The patients and families, stuck in the middle, seek clarity and safety in a sea of uncertainty.
The power dynamics are akin to a high-stakes poker game. Regulatory agencies and professional societies hold the cards when it comes to clinical practice and public policy. Critics may have less institutional clout, but their advocacy can sway public opinion. Medical experts, even the diplomatic dealers, balance risks and benefits, helping patients navigate the choppy waters of antidepressant use in pregnancy.
Current Developments and Ongoing Research
Fast forward to today, and the FDA’s stance has evolved. In 2011, the agency updated its communication, noting insufficient evidence linking SSRIs to persistent pulmonary hypertension of the newborn (PPHN). The forum’s debates are hotter than ever, as stakeholders dissect the latest findings and update recommendations. Ongoing research continues to scrutinize specific antidepressants, with paroxetine still under the spotlight for its potential cardiac risks.
Professional societies remain steadfast in their message: individualized risk-benefit analysis is crucial. Most SSRIs and tricyclic antidepressants are deemed relatively safe, except for paroxetine, which clinicians avoid if possible. The consensus is clear: untreated maternal depression poses significant risks, and abrupt discontinuation can lead to relapse and other adverse outcomes.
